• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Novartis Site Directory
Novartis logo : a global healthcare company
  • Our Work
    • Our Process
    • Clinical Trials
    • Clinical Pipeline
    • Product Portfolio
  • About Us
    • Who We Are
    • Our Business
    • Corporate Responsibility
    • Contact Us
    • AODA Compliant
    • Grants and Donations
    • AMA Compliant
    • Biome Canada, Montreal
  • Our Products
    • Pharmaceuticals
    • Health Care Professional
    • For Consumers
  • News
    • Media Releases
    • Media Contacts
    • Stories
    • FAQ
  • Careers
    • Careers Search
    • Working at Novartis
    • Employee Benefits
    • Student Programs
Search

News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

Advanced SearchBasic Search
2020

June

Media Release / Jun 19, 2020

Statement from Novartis on AVXS-101 filing with Health Canada

Read More
Media Release / Jun 16, 2020

Long-term, relapse-free survival data for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery presented at ASCO20

Read More

May

Media Release / May 27, 2020

Novartis in Canada responds to COVID-19 with commitments in key areas

Read More

April

Media Release / Apr 27, 2020

Novartis in Canada initiates Community Strong COVID-19 response program

Read More
Media Release / Apr 16, 2020

Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment

Read More
Media Release / Apr 15, 2020

Novartis recognized as one of the Best Workplaces™ in Canada

Read More

March

Media Release / Mar 17, 2020

Coronavirus disease (COVID-19) update

Read More
Media Release / Mar 03, 2020

Novartis receives Health Canada approval for MayzentTM (siponimod) to treat secondary progressive multiple sclerosis with active disease

Read More
2019

December

Media Release / Dec 16, 2019

British Columbia lists Tafinlar® plus Mekinist® for adjuvant treatment of melanoma patients with BRAF V600 mutation and lymph node involvement1

Read More
Media Release / Dec 12, 2019

Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)1

Read More
Search Results Navigation
  • First page « first
  • Previous page ‹ previous
  • Page 1 of 3
  • Current page 2 of 3
  • Page 3 of 3
  • Next page next ›
  • Last page last »
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email

You are here

  1. Home ›
  2. News

Novartis Canada

  • Our Work
  • About Us
  • Our Products
  • News
  • Careers
  • Contact Us
  • Locations
  • Biome Canada, Montreal

Subscribe to Novartis

  • Twitter
  • Linkedin
  • Novartis Site Directory
© 2021 Novartis Pharmaceuticals Canada inc.
  • Terms of Use
  • Privacy Policy

This site is intended for an audience in Canada.